The DOI matches its Crossref record; 382 of the 382 references it cites were found in a registry or an index.
G protein-coupled receptor kinases: More than just kinases and not only for GPCRs
Open accessAbstract
G protein-coupled receptor (GPCR) kinases (GRKs) are best known for their role in homologous desensitization of GPCRs. GRKs phosphorylate activated receptors and promote high affinity binding of arrestins, which precludes G protein coupling. GRKs have a multidomain structure, with the kinase domain inserted into a loop of a regulator of G protein signaling homology domain. Unlike many other kinases, GRKs do not need to be phosphorylated in their activation loop to achieve an activated state. Instead, they are directly activated by docking with active GPCRs. In this manner they are able to selectively phosphorylate Ser/Thr residues on only the activated form of the receptor, unlike related kinases such as protein kinase A. GRKs also phosphorylate a variety of non-GPCR substrates and regulate several signaling pathways via direct interactions with other proteins in a phosphorylation-independent manner. Multiple GRK subtypes are present in virtually every animal cell, with the highest expression levels found in neurons, with their extensive and complex signal regulation. Insufficient or excessive GRK activity was implicated in a variety of human disorders, ranging from heart failure to depression to Parkinson’s disease. As key regulators of GPCR-dependent and -independent signaling pathways, GRKs are emerging drug targets and promising molecular tools for therapy. Targeted modulation of expression and/or of activity of several GRK isoforms for therapeutic purposes was recently validated in cardiac disorders and Parkinson’s disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
G Protein–Coupled Receptor Kinase 2 Plays a Relevant Role in Insulin Resistance and Obesity
García‐Guerra, L., Nieto-Vázquez, I., Vila‐Bedmar, R., Jurado-Pueyo, M., Zalba, G., Díez, J., Murga, C., Fernández‐Veledo, S., Mayor, F., & Lorenzo, M. (2010) · Diabetes · doi:10.2337/db10-0771 · Cited by 97
RetractedMutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240 · cited 1×
“Although the function of synucleins remains unclear, they are of great medical interest because α-synuclein is the first gene to be implicated as a cause of a rare familial form of Parkinson's disease (Polymeropoulos et al., 1997).”
BackgroundAKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment
Baron, R., Binder, A., & Wasner, G. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70143-5 · Cited by 1,816
Structure of a nanobody-stabilized active state of the β2 adrenoceptor
Rasmussen, S. G. F., Choi, H.-J., Fung, J. J., Pardon, E., Casarosa, P., Chae, P. S., DeVree, B. T., Rosenbaum, D. M., Thian, F. S., Kobilka, T. S., et al. (2011) · Nature · doi:10.1038/nature09648 · Cited by 1,680
β-Arrestin-Dependent Formation of β 2 Adrenergic Receptor-Src Protein Kinase Complexes
Luttrell, L. M., Ferguson, S. S. G., Daaka, Y., Miller, W. E., Maudsley, S., Della Rocca, G. J., Lin, F.-T., Kawakatsu, H., Owada, K., Luttrell, D. K., et al. (1999) · Science · doi:10.1126/science.283.5402.655 · Cited by 1,475
The nuts and bolts of AGC protein kinases
Pearce, L. R., Komander, D., & Alessi, D. R. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2822 · Cited by 1,294
Cloning of the gene and cDNA for mammalian β-adrenergic receptor and homology with rhodopsin
Dixon, R. A. F., Kobilka, B. K., Strader, D. J., Benovic, J. L., Dohlman, H. G., Frielle, T., Bolanowski, M. A., Bennett, C. D., Rands, E., Diehl, R. E., et al. (1986) · Nature · doi:10.1038/321075a0 · Cited by 1,276
The role of dopamine in the pathophysiology of depression
Dunlop, B. W., & Nemeroff, C. B. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.3.327 · Cited by 1,244 · cited 1×
“The activity of multiple GPCRs is altered in the depressive state and affected by antidepressant treatment (Catapano & Manji, 2007; Dunlop & Nemeroff, 2007).”
BackgroundRoss, E. M., & Wilkie, T. M. (2000) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.69.1.795 · Cited by 1,156
Cited by
GPCR Signaling Regulation: The Role of GRKs and Arrestins
Gurevich, V. V., & Gurevich, E. V. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00125 · Cited by 545
Self-citationPathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
Bastide, M. F., Meissner, W. G., Picconi, B., Fasano, S., Fernagut, P.-O., Feyder, M., Francardo, V., Alcacer, C., Ding, Y., Brambilla, R., et al. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.07.002 · Cited by 475
Self-citationThe Concise Guide to PHARMACOLOGY 2013/14: Enzymes
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12451 · Cited by 425
Structural insights into G-protein-coupled receptor allostery
Thal, D. M., Glukhova, A., Sexton, P. M., & Christopoulos, A. (2018) · Nature · doi:10.1038/s41586-018-0259-z · Cited by 319
Estrogen-Receptor Expression and Function in Female Reproductive Disease
Tang, Z.-R., Zhang, R., Lian, Z.-X., Deng, S.-L., & Yu, K. (2019) · Cells · doi:10.3390/cells8101123 · Cited by 274
The Prostanoid EP4 Receptor and Its Signaling Pathway
Yokoyama, U., Iwatsubo, K., Umemura, M., Fujita, T., & Ishikawa, Y. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.007195 · Cited by 264
Prossnitz, E. R., & Arterburn, J. B. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009712 · Cited by 258
Ins and outs of GPCR signaling in primary cilia
Schou, K. B., Pedersen, L. B., & Christensen, S. T. (2015) · The EMBO Reports · doi:10.15252/embr.201540530 · Cited by 221
“…of heterotrimeric G proteins, although G protein-independent signaling mechanisms occur, for example via receptor-interacting proteins that regulate both agonist-promoted and agonist-inhibited GPCR signaling [7] as well as G protein-interacting protein cross talk with non-GPCR signaling [8,9].”
Lorton, D., & Bellinger, D. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16035635 · Cited by 221
MC 1R, the c AMP pathway, and the response to solar UV: extending the horizon beyond pigmentation
García‐Borrón, J. C., Abdel‐Malek, Z., & Jiménez‐Cervantes, C. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12257 · Cited by 187
Structures of rhodopsin in complex with G-protein-coupled receptor kinase 1
Chen, Q., Plasencia, M., Li, Z., Mukherjee, S., Patra, D., Chen, C.-L., Klose, T., Yao, X.-Q., Kossiakoff, A. A., Chang, L., et al. (2021) · Nature · doi:10.1038/s41586-021-03721-x · Cited by 152
Self-citationG protein–coupled receptors control the sensitivity of cells to the morphogen Sonic Hedgehog
Pusapati, G. V., Kong, J. H., Patel, B. B., Gouti, M., Sagner, A., Sircar, R., Luchetti, G., Ingham, P. W., Briscoe, J., & Rohatgi, R. (2018) · Science Signaling · doi:10.1126/scisignal.aao5749 · Cited by 91
Targeting G protein coupled receptor-related pathways as emerging molecular therapies
Ghanemi, A. (2015) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2013.07.007 · Cited by 53
“Although insufficient or excessive GRK activity is involved in a variety of pathologies, the pharmacological value of GRKs as potential targets remains under-appreciated (Gurevich et al., 2012).”
Influential
Metadata
- Authors
- Gurevich, E. V., Tesmer, J. J. G., Mushegian, A., & Gurevich, V. V.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2012-01
- Volume
- 133
- Issue
- 1
- Pages
- 40-69
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2026493203
- Cited by
- 423
- References
- 382
- FWCI
- 9.99
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.